• Biosecurity Is Too Important to Be Left Unregulated

    Bio-IT World | Recently, California became the first state to enact a law requiring nucleic acid synthesis companies to screen sequences and vet customers before delivering their products. California is a pioneer in creating enforceable regulations of nucleic acid synthesis screening. Unfortunately, it’s not enough.

    Nov 11, 2026
  • NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation

    Bio-IT World | A Pitt cardiologist’s startup, Amlysion Therapeutics, plans to develop NCOA7-activating drugs after new research traces cognitive decline in pulmonary hypertension to the same inflammatory pathway that drives the disease in the heart and lungs.

    Nov 10, 2026
  • Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award

    Bio-IT World | HuBMAP data portal opens 9,000 healthy-tissue datasets to researchers; NCI awards Montefiore Einstein $10 million to study breast cancer dormancy; UCB adds Cradle's protein design platform across its antibody discovery pipeline; NIH funds a $16.4 million hepatitis C vaccine center at Scripps Research; Transpharmation acquires organoid developer OrganoTherapeutics; new gene editing products from Integrated DNA Technologies and Aldevron; and more.

    Nov 7, 2026
  • Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences

    Bio-IT World | Emerging public-cloud ERP-based GxP compliance solutions will be good for life sciences businesses beyond just sharply reducing compliance overhead. Public-cloud ERP GxP will ensure product quality and patient safety, speed up innovation, stoke growth, appeal to investors, improve responsiveness to market moves, smooth M&A efforts, and enable AI-driven efficiencies.

    Nov 5, 2026
  • Quantifying the Average Human Genome

    Bio-IT World | Mining two mega-datasets totaling over 900,000 sequenced genomes, researchers in the UK produced the broadest look yet at what a typical human genome contains and found that “normal” can look alarming on paper. “Variation is the norm,” they found. The work was published October in Genome Medicine.

    Nov 3, 2026
  • Regulatory Affairs Is the Connective Tissue Pharma’s AI Strategy Is Missing

    Bio-IT World | Every major pharma organization I’ve come across in recent years has its own version of the same AI-based ambition. It is looking to use the technology to compress the R&D timeline, reduce late-stage attrition, and make regulatory submissions faster and inspections less tense. And yet, almost without exception, progress will stall because the product data foundations are flawed.

    Oct 29, 2026
  • Follow the Money: OMass Raises Series C, Pathos AI Drug Development, Owkin Alums Launch Rivercell

    Bio-IT World | Matchpoint Therapeutics closes $150M Series B for oral autoimmune drugs; Soufflé Therapeutics raises $135M to take siRNA beyond the liver; WhiteLab Genomics adds $26M for AI-designed gene therapy delivery; and more.

    Oct 28, 2026